Frovatriptan succinate is used to treat migraine headaches. It works by binding to serotonin receptors in the brain and blood vessels to relieve pain and inhibit dilation of blood vessels. Common side effects include dizziness, fatigue, nausea, and chest pain. It should be used cautiously in patients with risk factors for heart disease due to potential cardiovascular side effects like arrhythmias and myocardial ischemia. The recommended dosage is 2.5 mg taken orally as needed for migraine symptoms.

1. DRUG PRESENTATION
ON
Frovatriptan Succinate
PRESENTED TO: PRESENTED BY:
Ms. Harneetpal Kaur. Ishika sharma
Tutor BSc Nursing
ACON 3rd Year (2019-23)

2. WHAT IS FROVATRIPTAN SUCCINATE

3. INTRODUCTION
•Frovatriptan is used to treat the symptoms of migraine headaches (severe throbbing headaches that
sometimes are accompanied by nausea and sensitivity to sound and light)
 Generic name: Frovatriptan succinate.
 Brand name: Frovatriptan
 Pharmacological name: 5-hydroxytryptamine (5-HT1) receptor agonist ,triptam.
 Classification: Frovatriptan is in a class of medication called Selective serotonin receptor agoinst.
 Therapeutic Class: Antimigraine agent.
 Pregancy category: C.
Available forms:
• Tablets :- 2.5 mg ( Round white,film coated tablets with 2.5 on side E on the other side.
• The recommended dose is a single tablet of frova (frovatriptan 2.5 mg) taken orally with fluids.

4. Usual Dosage:
• Adults – 2.5 mg
• Children – <18 yrs not recommended
• Geriatric – 2.5 mg per oral.
Route: Oral ( Half life = 26 hrs) Max – 7.5 mg daily.

5. MECHANISM OF ACTION
•Binds to 5-HT1B and 5-HT1D receptors on extracerebral and
intracranial arteries to inhibits excessive dilation of these
vessels. This action may decrease carotid arterial blood flow ,
thus relieving acute migrains.
Frovatriptan may also relieve pain by inhibiting the release of
proinflammatory neuropeptids and reducing transmission of
trigeminal nerve impulse from sensory nerve ending during a
migrane attack.

6.  Absorption:- Frovatriptan is rapidally absorbed from the duodenum but has low
oral bioavailability.
 Distribution:- Volume of distribution
4.2 L/kg(Males).
3L/kg(Females)
 Metabolism:- In vitro ,cytochrome P4501A2 appears to be the prinicipal enzyme
involved in the metabolism of frovatriptan to several metabolism including
hydroxylated frovatriptan , N-acetyl desmethyl frovatriptan and desmethyl
frovatriptan & several other minor metabolities. The other activity of the other
metabolities is Unknown.
 Excretion:-10% of frovatriptan was excreted in the urine after an oral.
 Half life = 26 hours.

7.  Frova is indicated for the Acute treatment of migraine with or without
aura in adults.
 Limitations of Use…..
 Use only if a clear diagnosis of migraine has established.If a patient has no
response for the first migraine attack treated with FROVA reconsider the
diagnosis of migraine before FROVA is administred to treat any
subsequent.
 Safety and effectiveness of FROVA has not been established for cluster
headache.

8. Ischemic coronary artery disease.
Wolf – Parkinson’s white syndrome.
History of stroke,iscemic attack or history of hemiplegia.
Peripheral vascular disease.
Ischemic bowel disease.
Uncontrolled hypertension.
Hypersensitivity to frova.

9.  Myocardial Ischemia,Myocardial Infraction
 Prinzmetal Angina
 Arrhythmias
 Chest,Throat,Neck and Jaw pain
 Cardiovascular Events
 Serotonin syndrome
 Increase in Blood pressure
 Anaphylactic / Anaphylatic Reactions.

10. 1.CNS=Anixety,dizziness,dysesthesia,fatigue,headache,hypoesthesis,insom
nia,paresthesia,seizures,serotonin syndrome.
2.CV= Arrhythmias,Chest pain, coronaryartery vasospasm,ECG
changes,MI,Myocardial ischemia,
palpitations,ventricular,fibrillation,ventricular,tachycardia.
3.EENT= Abnormal vision, dry mouth,indigestion,rhinits,sinusits,tinnitus.
4.GI= Abdominal pain,diarrhea,indigestion,vomiting.
5.MS= Skeletal pain
6.SKIN=Diaphoresis,flushing
Other= Generalised pain

12.  Use frovatriptan cautiously in patients with peripheral vascular disease
because drug may cause vasospastic reactions, leading to vascular and
colonic ischemia with abdominal pain and bloody diarrhea.
 Assess patient’s peripheral circulation and bowel sounds during
frovatriptan therapy.
 Don’t give frovatriptan within 24 hours of another 5-HT1 receptor agonist,
such as sumatriptan or rizatriptan, or of an ergotamine-containing or
ergot-type drug, such as dihydroergotamine or methysergide.
 Administer tablet with fluids.
 Assess patient for headache before administering second dose. Don’t
administer more than three 2.5-mg tablets a day.

13.  Assess patient’s cardiovascular status and institute continuous ECG
monitoring, as ordered, immediately after drug admin istration in
patients with cardiovascular risk factors because they’re at risk for
asymptomatic cardiac ischemia.
 Assess patient for arrhythmias, chest pain, and other signs of heart disease
in patients with risk factors for CAD. Expect to assess periodically
cardiovascular status of patients on long-term therapy.
 Be aware that the safety of treating more than four migraine attacks in 30
days (on average) has not been established.
 Regularly monitor blood pressure of hypertensive patients during therapy
because frovatriptan may produce a transient increase in blood pressure.

14.  Instruct patient to read and follow manufacturer’s instructions for using
frovatriptan to ensure maximum therapeutic results
 Remind patient not to exceed prescribed daily dosage.
 Encourage patient to lie down in a dark, quiet room after taking drug to
help relieve migraine. •Instruct patient to seek emergency care for chest,
jaw, or neck tightness after drug use because drug may cause coronary
artery vasospasm.
 Urge patient to report palpitations.
 Caution patient about possible adverse CNS effects, and advise her to
avoid hazardous activities until drug’s CNS effects are known.
 Emphasize need to report any unusual or serve symptoms immediately.

15. REFERENCES
 From textbook:-
 Textbook of pharmacology,pathology and genetics for nurses by Dr.suresh K sharma
 From Internet resources;-
 https://www.drugs.com/tips/frovatriptan.
 Nurse’s drug Handbook page no:-568
 http;//www.drugs.com.